Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.48 |
| ▸ | ELOC | Q15369 | 1/20 | 0.48 |
| ▸ | ELOB | Q15370 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917355 | 0.77 | LOXL2 (0.46) | NOS3NOS1 | |
| SCHEMBL12523289 | 0.77 | NPC1 (0.46) | TSHRTP53SMN1; SMN2 | |
| SCHEMBL2130992 | 0.75 | CFTR (0.49) | CYP11B1CYP11B2PRSS1PRSS2PRSS3 | |
| SCHEMBL18381606 | 0.74 | LOXL2 (0.50) | NOS3NOS1CA12CA1CA2 | |
| SCHEMBL12844556 | 0.74 | MGLL (0.48) | CA1CA2PTGS2 | |
| SCHEMBL1185636 | 0.73 | ENPP2 (0.45) | MKNK1MKNK2CA12CA1CA2 | |
| SCHEMBL23514708 | 0.72 | PTGS1 (0.39) | TSHRCHRM1PTGS2 | |
| Hydrochloric Acid SCHEMBL20508979 | 0.72 | LOXL2 (0.48) | NOS3NOS1SMN1; SMN2 | |
| SCHEMBL20782068 | 0.72 | HRH3 (0.50) | TSHRNOS3NOS1 | |
| SCHEMBL11132652 | 0.72 | KDM4E (0.59) | VHLELOCELOBTSHRP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12365670-B2 | GLP-IR agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-10844049-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-10844049-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-7659293-B2 | α-Amino-N-hydroxy-acetamide derivatives | NOVARTIS AG (CH) | 2010-02-09 | — | — | US | disclosed |
| US-20080176916-A1 | A-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2008-07-24 | — | — | US | disclosed |
| US-7291634-B2 | α-amino-N-hydroxy-acetamide derivatives | NOVARTIS AG (CH) | 2007-11-06 | — | — | US | disclosed |
| US-20060270719-A1 | 2-[(Cyclopropylmethoxy-benzenesulfonyl)-(4-[1,2,3]triazol-2-yl-benzyl)-amino]-N-hydroxy-acetamide; selective inhibitors of matrix-degrading metalloproteinases, especially MT1-MMP, MMP-2 and MMP-9; Osteoporosis; Antitumor, antiproliferative agents | NOVARTIS AG (CH) | 2006-11-30 | — | — | US | disclosed |
| US-7112611-B2 | 1g(α)-amino-N-hydroxy-acetamide derivatives | NOVARTIS AG (CH) | 2006-09-26 | — | — | US | disclosed |
| US-20040082630-A1 | 1g(a)-Amino-n-hydroxy-acetamide derivatives | NOVARTIS AG (CH) | 2004-04-29 | — | — | US | disclosed |
| EP-1360175-A1 | 1G(A)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | Novartis AG (CH) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002064552-A1 | 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | VHL 3882/4885ELOC 4845/4885ELOB 4705/4885 |
| US-20060270719-A1 | 2-[(Cyclopropylmethoxy-benzenesulfonyl)-(4-[1,2,3]triazol-2-yl-benzyl)-amino]-N-hydroxy-acetamide; selective inhibitors of matrix-degrading metalloproteinases, especially MT1-MMP, MMP-2 and MMP-9; Osteoporosis; Antitumor, antiproliferative agents | MMP9, MMP14, MMP13 | VHL 1016/4885ELOC 4179/4885ELOB 3654/4885 |
| US-10844049-B2 | GLP-1R agonists and uses thereof | GLP1R, GPR119, GIPR | VHL 3730/4885ELOC 4453/4885ELOB 3307/4885 |
| US-12365670-B2 | GLP-IR agonists and uses thereof | GLP1R, GPR119, GIPR | VHL 4240/4885ELOC 4564/4885ELOB 3086/4885 |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | VHL 3730/4885ELOC 4453/4885ELOB 3307/4885 |
| US-20080176916-A1 | A-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | MMP1, MMP9, MMP14 | VHL 586/4885ELOC 3665/4885ELOB 2892/4885 |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | VHL 3822/4885ELOC 4477/4885ELOB 2917/4885 |
| US-20040082630-A1 | 1g(a)-Amino-n-hydroxy-acetamide derivatives | MMP1, MMP9, MMP13 | VHL 725/4885ELOC 3914/4885ELOB 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.